StreetInsider.com News Articles

CRISPR Therapeutics (CRSP) Reiterated at Market Outperform by Citizens Ahead of Key Data

Wed, 22 Jul 2026 04:13:47 -0400

Citizens analyst Silvan Tuerkcan reiterated a Market Outperform rating and $80.00 price target on CRISPR Therapeutics (NASDAQ: CRSP).

The analyst commented, "Overall, we view CRSP as attractive at these levels, ahead of several key datasets in 2H26 as the company is building toward a pipeline of late-stage assets (especially in-vivo) across large CVD/metabolic indications. Key data include: 1) 2H26 – CTX611 update in TKA patients that should put this asset on the map; 2) 2H26 – CTX310 data; 3) 2H26 – Zugo-Cel data in oncology and I&I, where we like the addition of less-competitive patient populations. Investors are wary of gene

H.C. Wainwright Reiterates Buy Rating on CRISPR Therapeutics (CRSP)

Wed, 08 Jul 2026 06:41:25 -0400

H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating and $80.00 price target on CRISPR Therapeutics (NASDAQ: CRSP).

The analyst commented: "The FDA has expanded CASGEVY's label to patients two years and older with sickle cell disease (SCD) with recurrent vaso-occlusive crises (VOCs) or transfusion-dependent beta-thalassemia (TDT), vs. the prior 12+ label. Importantly, safety and efficacy were evaluated in 5-to-<12-year cohorts, and the agency granted extrapolation down to younger pediatrics based on product characteristics and clinical data. In our view, that rationale is suggestive that the FDA is comfortable extending the ex vivo CRISPR/HSC-editing profile beyond the directly studied population, with

CRISPR Therapeutics (CRSP) Reiterated at Market Outperform by Citizens

Mon, 06 Jul 2026 04:52:03 -0400

Citizens analyst Silvan Tuerkcan reiterated a Market Outperform rating and $80.00 price target on CRISPR Therapeutics (NASDAQ: CRSP).

The analyst commented, "We estimate the expansion of the CASGEVY label into patients 2 or older could increase the TAM by 10-15%. A key question will be around fertility in young patients. High response/cure rates (100%) demonstrated in CLIMB-151 (SCD) and CLIMB-141 (TDT) presented at EHA (5-11 year olds) emphasize the value proposition. We view limited risk from Beam's (BEAM, NC) risto-cel displacing CASGEVY, as 1) efficacy alone is unlikely to displace exa-cel and base-editing benefits are small (fewer days to graft) or

CRISPR Therapeutics (CRSP) Reiterated at Market Outperform by Citizens

Fri, 12 Jun 2026 04:11:00 -0400

Citizens analyst Silvan Tuerkcan reiterated a Market Outperform rating and $80.00 price target on CRISPR Therapeutics (NASDAQ: CRSP).

The analyst commented, "CRISPR Therapeutics' partner Vertex Pharmaceuticals (VRTX, NC) presented Casgevy data in children ages 5–11 at EHA which underpins regulatory filings in this younger age cohort in several countries; we believe this should increase the Casgevy patient population by 10-15%. CRISPR Therapeutics is building toward a pipeline of late-stage assets (especially in-vivo) across large CVD/metabolic indications, with key early readouts in 2H26, supported by an inflection in Casgevy sales. We maintain our Market Outperform rating and $80 DCF-derived price target ahead

Morgan Stanley Assumes CRISPR Therapeutics (CRSP) at Equalweight

Thu, 11 Jun 2026 04:23:20 -0400

Morgan Stanley analyst Maxwell Skor assumes coverage on CRISPR Therapeutics (NASDAQ: CRSP) with a Equalweight rating and a price target of $60.00.

The analyst comments: “We assume coverage of CRISPR Therapeutics (CRSP) at an Equal-weight rating and $60 price target. While Casgevy (exa-cel) represents the first FDA-approved CRISPR/Cas9 gene-editing therapy and is building toward a multi-billion-dollar opportunity in partnership with Vertex (covered by Terence Flynn), we view the stock as a “show-me” story at current levels, with much of the near-term Casgevy upside already reflected in the valuation. The central debate is whether Casgevy can transition from a complex, capacity-constrained cell

Morgan Stanley Assumes CRISPR Therapeutics (CRSP) at Equalweight

Thu, 11 Jun 2026 04:23:20 -0400

Morgan Stanley analyst Maxwell Skor assumes coverage on CRISPR Therapeutics (NASDAQ: CRSP) with a Equalweight rating and a price target of $60.00.

Form 4 CRISPR Therapeutics AG For: Jun 05 Filed by: George Simeon

Tue, 09 Jun 2026 18:09:00 -0400

si-local-file:///var/storage/secattach/20260609/26625047.html

Form 4 CRISPR Therapeutics AG For: Jun 05 Filed by: George Simeon

Tue, 09 Jun 2026 18:09:00 -0400

si-local-file:///var/storage/secattach/20260609/26625047.html

Form 4 CRISPR Therapeutics AG For: Jun 05 Filed by: Behbahani Ali

Tue, 09 Jun 2026 18:06:00 -0400

si-local-file:///var/storage/secattach/20260609/26625034.html

Form 4 CRISPR Therapeutics AG For: Jun 05 Filed by: Behbahani Ali

Tue, 09 Jun 2026 18:06:00 -0400

si-local-file:///var/storage/secattach/20260609/26625034.html

Form 4 CRISPR Therapeutics AG For: Jun 05 Filed by: Fardis Maria

Tue, 09 Jun 2026 17:44:00 -0400

si-local-file:///var/storage/secattach/20260609/26624961.html

Form 4 CRISPR Therapeutics AG For: Jun 05 Filed by: Fardis Maria

Tue, 09 Jun 2026 17:44:00 -0400

si-local-file:///var/storage/secattach/20260609/26624961.html

Form 4 CRISPR Therapeutics AG For: Jun 05 Filed by: Greene John

Tue, 09 Jun 2026 17:43:00 -0400

si-local-file:///var/storage/secattach/20260609/26624955.html

Form 4 CRISPR Therapeutics AG For: Jun 05 Filed by: Greene John

Tue, 09 Jun 2026 17:43:00 -0400

si-local-file:///var/storage/secattach/20260609/26624955.html

Form 4 CRISPR Therapeutics AG For: Jun 05 Filed by: Fleming Harold Edward

Tue, 09 Jun 2026 17:43:00 -0400

si-local-file:///var/storage/secattach/20260609/26624958.html

Form 4 CRISPR Therapeutics AG For: Jun 05 Filed by: Fleming Harold Edward

Tue, 09 Jun 2026 17:43:00 -0400

si-local-file:///var/storage/secattach/20260609/26624958.html

Form 4 CRISPR Therapeutics AG For: Jun 05 Filed by: Mahatme Sandesh

Tue, 09 Jun 2026 17:42:00 -0400

si-local-file:///var/storage/secattach/20260609/26624953.html

Form 4 CRISPR Therapeutics AG For: Jun 05 Filed by: Mahatme Sandesh

Tue, 09 Jun 2026 17:42:00 -0400

si-local-file:///var/storage/secattach/20260609/26624953.html

Form 4 CRISPR Therapeutics AG For: Jun 05 Filed by: High Katherine A

Tue, 09 Jun 2026 17:42:00 -0400

si-local-file:///var/storage/secattach/20260609/26624954.html

Form 4 CRISPR Therapeutics AG For: Jun 05 Filed by: High Katherine A

Tue, 09 Jun 2026 17:42:00 -0400

si-local-file:///var/storage/secattach/20260609/26624954.html

Form 4 CRISPR Therapeutics AG For: Jun 05 Filed by: Rommel Christian

Tue, 09 Jun 2026 17:41:00 -0400

si-local-file:///var/storage/secattach/20260609/26624949.html

Form 4 CRISPR Therapeutics AG For: Jun 05 Filed by: Rommel Christian

Tue, 09 Jun 2026 17:41:00 -0400

si-local-file:///var/storage/secattach/20260609/26624949.html

Form 4 CRISPR Therapeutics AG For: Jun 05 Filed by: Morrison Briggs

Tue, 09 Jun 2026 17:41:00 -0400

si-local-file:///var/storage/secattach/20260609/26624951.html

Form 4 CRISPR Therapeutics AG For: Jun 05 Filed by: Morrison Briggs

Tue, 09 Jun 2026 17:41:00 -0400

si-local-file:///var/storage/secattach/20260609/26624951.html

Form 4 CRISPR Therapeutics AG For: Jun 05 Filed by: Treco Douglas A

Tue, 09 Jun 2026 17:40:00 -0400

si-local-file:///var/storage/secattach/20260609/26624946.html